MedPath

Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders

Phase 4
Conditions
Infertility
Interventions
Other: mild stimulation protocol
Other: controlled ovarian stimulation
Registration Number
NCT01926210
Lead Sponsor
Huang Rui
Brief Summary

This is a prospective, randomized clinical trial to compare the efficiency and safety of mild stimulation and controlled ovarian stimulation protocol on the treatment of POR. The randomization is achieved on the basis of a computer-generated randomization list in a 1:1 ratio.

Detailed Description

500 poor ovarian responders will be equally randomized to two different ovarian stimulation protocol arms,i.e, mild ovarian stimulation(experimental arm) or controlled ovarian stimulation(control arm). In experimental arm, patients will received letrozole 5mg per day from cycle day 3 to 7 and recombinant follicle-stimulating hormone (FSH) 150 international unit (IU) on day 4 and 6. The dose of recombinant FSH is adjusted according to the ovarian response and the gonadotropin-releasing hormone(GnRH)antagonist(Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum luteinizing hormone (LH)level rises above 2 times of basal LH level. In control arm,patients will be stimulated with short-acting GnRH agonist long protocol. After complete downregulation is achieved through GnRH-agonist, recombinant FSH 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.

The clinical and ongoing pregnancy rate and other secondary outcome parameters are compared between these two groups.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
500
Inclusion Criteria
  • a. Poor ovarian responders b. Normal BMI (18-25 Kg/m2) c. Regular menstruation (with cycle 23-35 days)
Exclusion Criteria
  • a. History of repeated IVF failure (previous IVF cycle >2) b. Serious adenomyosis c. Polycystic ovary syndrome(PCOS) patients d. History of allergic to ovulation induction medicines e. Abnormal uterine cavity, i.e, intrauterine adhesion f. Attending other clinical trials in the same period. g. History of systemic disease contradictory to COH or pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
mild ovarian stimulationmild stimulation protocolPatients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
controlled ovarian stimulationcontrolled ovarian stimulationPatients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
Primary Outcome Measures
NameTimeMethod
clinical pregnancy rate7 weeks
Secondary Outcome Measures
NameTimeMethod
live birth rate10 months
Number of oocytes retrieved3 weeks
Number of transferrable embryo3 weeks
normal fertilization rate3 weeks
implantation rate7 weeks
ongoing pregnancy rate3 months
Total dose of recombinant FSH consumption3 weeks
length of stimulation3 weeks
serum estradiol level3 weeks
serum LH level3 weeks
serum progesterone level3 weeks
serum FSH level3 weeks
FSH level in follicular fluid3 weeks
LH level in follicular fluid3 weeks
Estradiol level in the follicular fluid3 weeks
progesterone level in follicular fluid3 weeks
testerone level in the follicular fluid3 weeks
anti-müllerian hormone (AMH)level in follicular fluid3 weeks
Ovarian Hyperstimulation Syndrome (OHSS) rate7 weeks

Trial Locations

Locations (1)

sixth affiliated hospital of Sun Yet-san University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath